What is the mechanism of action of Keltican (uridine‑5′‑monophosphate, folic acid, vitamin B12) and what is the current clinical evidence supporting its use for peripheral neuropathic pain?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 7, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Keltican: Mechanism of Action and Clinical Evidence

Keltican (uridine-5'-monophosphate + folic acid + vitamin B12) is a neurotrophic combination that theoretically supports myelin regeneration and nerve repair, but it is NOT recommended as first-line therapy for peripheral neuropathic pain based on current high-quality guidelines.

Mechanism of Action

Keltican works through three complementary pathways:

  • Uridine monophosphate (UMP): Acts as a pyrimidine nucleotide precursor that provides building blocks for phospholipid synthesis in myelin-producing Schwann cells, theoretically supporting myelin sheath regeneration after nerve injury 1
  • Folic acid: Participates in one-carbon metabolism, supporting DNA synthesis, methylation reactions, and potentially reducing homocysteine levels that may contribute to nerve damage 2, 3
  • Vitamin B12 (hydroxocobalamin): Serves as an essential coenzyme in mitochondrial energy metabolism, myelin maintenance, and neurotransmitter synthesis 2

The proposed mechanism centers on providing metabolic substrates for nerve repair rather than direct analgesic effects 1, 4.

Current Clinical Evidence

Evidence Quality Assessment

The evidence for Keltican consists primarily of small, open-label, observational studies with significant methodological limitations:

  • A 2014 open-label study (n=212) showed pain reduction from 17.5 to 8.8 points on painDETECT questionnaire over 2 months 1
  • A 2016 study in entrapment neuropathies (n=48) demonstrated similar pain score improvements 5
  • A 2002 study (n=40) in diabetic polyneuropathy showed trends toward improvement but only achieved statistical significance for sural nerve conduction velocity 6

Critical limitations: No randomized, placebo-controlled trials; no blinding; short follow-up periods (2-3 months); high risk of placebo effect and regression to the mean.

Guideline-Based Recommendations

For diabetic peripheral neuropathy, the highest quality guidelines clearly establish first-line therapy 7, 8, 9:

  • Pregabalin, duloxetine, or gabapentin are the recommended initial pharmacologic treatments 7
  • Duloxetine (60-120 mg/day) has NNT of 4.9-5.2 for ≥50% pain reduction 10
  • Pregabalin (150-600 mg/day) has NNT of 4.04-5.99 10
  • Gabapentin (up to 3600 mg/day) is established as effective 10

For chemotherapy-induced peripheral neuropathy, duloxetine is the only agent with sufficient evidence for recommendation 11.

For chronic cancer pain, anticonvulsants (gabapentin, pregabalin) and antidepressants (venlafaxine) have the best evidence 12.

Position in Treatment Algorithm

Keltican does not appear in any major guideline as a recommended therapy 7, 11, 7, 12, 8, 10, 9. The evidence hierarchy clearly places it below:

  1. First-line: Pregabalin, duloxetine, gabapentin
  2. Second-line: Tricyclic antidepressants (amitriptyline, nortriptyline), SNRIs (venlafaxine)
  3. Third-line: Topical agents (capsaicin 8%, lidocaine patches), tramadol (with caution)
  4. Not recommended: Opioids (except tramadol/tapentadol with extreme caution due to addiction risk) 7, 8, 9

Clinical Interpretation

While the mechanistic rationale for Keltican is biologically plausible—providing substrates for myelin repair and supporting one-carbon metabolism—the clinical evidence does not meet the standards required for guideline inclusion. The available studies lack:

  • Randomized, double-blind, placebo-controlled design
  • Adequate sample sizes
  • Long-term follow-up (most neuropathic pain is chronic)
  • Head-to-head comparisons with established therapies
  • Objective outcome measures beyond subjective pain scores

If considering Keltican in clinical practice, it should only be:

  • After failure of guideline-recommended first-line agents (pregabalin, duloxetine, gabapentin)
  • After failure of second-line agents (TCAs, other SNRIs)
  • With explicit patient counseling about limited evidence
  • As adjunctive therapy, not monotherapy
  • With clear documentation of treatment rationale and monitoring plan

The combination's excellent safety profile (minimal adverse events reported) 1, 5 may make it reasonable for trial in refractory cases, but patients must understand they are receiving a treatment without high-quality evidence supporting efficacy, particularly when compared to established therapies with NNTs of 4-6 and robust RCT data 10.

Note: The FDA drug label information provided 13 pertains to ketorolac (an NSAID), not Keltican, and should be disregarded for this question.

References

Research

[Adjuvant therapy of pain syndromes: possibilities of using nucleotides].

Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 2019

Guideline

american association of clinical endocrinology clinical practice guideline: developing a diabetes mellitus comprehensive care plan-2022 update.

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologist, 2022

Related Questions

What evidence supports the use of Keltican (uridine‑5′‑monophosphate di‑sodium, vitamin B12, folic acid) in older adults with peripheral neuropathy and in patients after stroke?
What is the clinical use of a combination of Uridine-5'-monophosphate disodium salt + Vitamin B12 (Cobalamin) + Folic Acid 75.72 mg/ 3 micrograms (mcg)/ 400 mcg?
Can Keltican (uridine monophosphate, vitamin B12, folic acid) cause drowsiness?
What evidence supports the use of Keltican (thiamine, pyridoxine, cyanocobalamin, calcium, magnesium) for diabetic peripheral neuropathy?
Are there any contraindications or usage restrictions for thiamine 100 mg, riboflavin 2.54 mg, niacinamide 100 mg, panthenol 5 mg, and methylcobalamin 125 µg?
In a 46-year-old man with five-year primary infertility, right testicular atrophy, left normal testis, bilateral epididymitis on ultrasound, elevated prolactin, elevated luteinizing hormone, normal follicle‑stimulating hormone, low‑normal testosterone, and a normal 46,XY karyotype without Y‑chromosome microdeletions, what is the appropriate management?
What are the recommended next treatment guidelines for a patient with an unknown diagnosis, disease stage, comorbidities, age, and current therapies?
Is bempedoic acid appropriate for a patient with hyperuricemia (high serum uric acid) and what monitoring is recommended?
Are premature heartbeats occurring every five minutes dangerous?
What is the appropriate follow‑up protocol for a patient with low‑grade mucoepidermoid carcinoma of the parotid who is one year post‑surgical resection?
How can I dilute voriconazole for a pediatric patient when the prescribed dose is 80 mg twice daily but only 50 mg film‑coated tablets are available?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.